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ABSTRACT
With the proliferation of outcome measures in the literature,
many of which lack documentation of sufficient psychometric
properties to justify use, it is difficult to document patient change
or demonstrate effectiveness of interventions. The goal of the
Section on Research’s EDGE (Evaluation Database to Guide
Effectiveness) Task Force is to facilitate identification of valid
and reliable tests and measures that reflect clinically important
outcomes and are responsive to change for standard use across
selected patient groups. This paper lays the groundwork for
understanding the work of the Oncology Section’s Breast Cancer
EDGE Task Force on clinical measures of shoulder function
including range of motion and muscle length, upper extremity
function, and scapular position and movement, as reported in the
3 papers that follow.
INTRODUCTION
The importance of outcome measurements to assess effectiveness of interventions has long been recognized. The physical
therapy profession has answered this need with the development
of many such measures. A search of the term outcomes measurement in PubMed1 yielded 12,138 hits. A search of the term
outcomes measurements in physical therapy yielded 633 hits. As
the variety of outcomes measurements proliferated, two concerns
emerged. The first concern was over the quality of the measurements that led to an increased emphasis on ascertaining and documenting the psychometric properties of tests and measurements.
In 1993, the American Physical Therapy Association (APTA)
published the Primer on Measurement: An Introductory Guide to
Measurement Issues2 to educate researchers and clinicians alike
on important considerations in development and use of tests and
measures. Many journals now require that outcomes reported in
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submitted papers include information on references that support
the psychometric properties and clinical utility of the measures.
The second concern in the proliferation of tests and measures
is the variety and disparate nature of the tests and measures,
even across similar outcomes. The desirability of reducing the
number of tests and measures being used within certain domains
and promoting select common or ‘standard’ measures became
evident. Deyo et al3 advocated for standardization in measurement of patient outcomes in order to:
• improve comparability of results among clinical studies;
• improve comparability of baseline patient characteristics
among clinical studies;
• facilitate meta-analysis;
• facilitate cost-effectiveness analysis by creating an accepted
metric for effectiveness;
• encourage more complete reporting of relevant outcomes;
• facilitate conduct of multicenter studies;
• facilitate design and review of manuscripts, publications,
research proposals; and
• avoid ‘reinventing the wheel.’
EDGE TASK FORCE BACKGROUND
In an effort to foster standardization of outcomes measurements in physical therapy, the APTA’s Section on Research
supported the formation of a task force led by Edelle FieldFote, PT, PhD. The EDGE (Evaluation Database to Guide
Effectiveness) Task Force brought together experts in evaluation
of tests and measures and in examination-based classification
of patients at APTA’s Combined Sections Meeting in 2006. The
group agreed that standardization of outcomes in a particular
domain was a necessary step in the process of accumulating
evidence on the effectiveness of a treatment approach in that
domain. According to Field Fote et al,4 “the bottom line is
that evidence of intervention effectiveness depends on, among
other things, common use of valid and reliable tests/measures
that reflect clinically important outcomes and are responsive to
change.” The EDGE Task Force goals were to:
Rehabilitation Oncology
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• e stablish a framework to facilitate the evaluation of
outcome measures,
• assist stakeholder groups (ie, Section Research Chairs,
SIGs, Specialty Councils) in evaluating outcome measures
within their practice/content areas, and
• assist in promoting the use of a core set.
Using a literature and consensus-based iterative process, the
EDGE Task Force developed a form for evaluation of a selected
outcome measure. The purpose of the form was to provide criteria important in determining whether a measure is appropriate
as a ‘standardized’ assessment tool and suitable for inclusion in
a ‘core set’ in a particular clinical domain. Through use of the
form, assessment of an outcome measure would be thorough and
consistent among evaluators and across tools.
After completion of its assessment form, the EDGE Task
Force expanded its membership to include representatives from
the clinical sections of the APTA, with the goal of having the
Sections carry the work forward to their particular areas of
interest. The Neurology Section was the first Section to apply
EDGE assessment to a practice area. The StrokEDGE Task
Force led by Jane Sullivan, PT, DHS, and Genevieve Pinto-Zipp,
PT, EdD, reviewed outcomes used in individuals who had a
stroke. This Task Force also developed a 4-point ordinal scale to
rank their recommendations for each outcome measure5 (Table
1). StrokEDGE disseminated its recommendations through the
Neurology Section Web site.5
As part of the ongoing progression of the EDGE Task
Force work, the APTA’s Oncology Section formed the Breast
Cancer EDGE Task Force in 2010 under the leadership of Laura
Gilchrist, PT, PhD. The working group employed a similar
strategy to that of StrokEDGE, using the domains of the World
Health Organization’s International Classification of Functioning,
Disability and Health (ICF).6 The group agreed on 8 subdomains
under Body Structure and Function and 11 subdomains under
Activities and Participation that were appropriate to individuals
who had been treated for breast cancer. The group also assessed
the original EDGE assessment form and the StrokEDGE form.
Table 1. StrokeEDGE Rating Scale1

4

Highly
Recommend

Highly recommended; the outcome measure has
excellent psychometric properties and clinical
utility.

3

Recommend

Recommended; the outcome measure has good
psychometric properties and good clinical utility.

2

Unable to
Recommend at
this time

Unable to recommend at this time; there is insufficient information to support a recommendation
of this outcome measure.

1

Do not
Recommend

Not recommended. The outcome measure has
poor psychometric properties and/or poor clinical
utility.

http://neuropt.org/go/healthcare-professionals/neurology-section-outcomemeasures-recommendations

1
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A few additional modifications were made to include criteria
that were relevant to measurement tools that would be evaluated
for use in the cancer population. The final CancerEDGE form
approved for use by the group can be found in the Appendix.
The first practice area the Breast Cancer EDGE group chose
was outcome measures relevant to shoulder and upper quarter
function in individuals treated for breast cancer. Measurements
of lymphedema were excluded because outcomes related to
lymphedema were determined to be a separate subdomain. The
Shoulder Subgroup is the first Oncology EDGE group to examine
relevant outcome measures for the cancer population.
SHOULDER DYSFUNCTION ASSOCIATED WITH
TREATMENT FOR BREAST CANCER
It is now widely acknowledged that various elements in the
treatment for breast cancer can produce both early (less than one
year) and late (greater than one year) adverse effects on shoulder
function, including range of motion (ROM) strength deficits, and
reported declines in quality of life. Furthermore, effects of treatment are considered to be multifactorial, including but not necessarily limited to type of surgery, degree of axillary node resection,
radiation, prior shoulder problems, and age.7-14 Such effects
have been found after treatment when comparing pre-op to postop values, when comparing involved to uninvolved sides, and
when comparing those treated for breast cancer to an unaffected
control group.15-19 Documenting the incidence and magnitude of
dysfunction or identifying treatment factors that increase the risk
for dysfunction has been challenging because of the variety of
assessment strategies used in different studies.
The absence of standardized measurements for shoulder
dysfunction limits the ability to compare study findings across
treatment factors and populations.11,20 In their systematic review,
Levangie and Drouin17 looked at studies that compared several
treatment factors, including chest wall radiation to more extensive
radiation, and axillary node clearance to sentinel node biopsy.
They found that the magnitudes of effect varied across studies
dramatically from small (standardized effect sizes of ≤ 0.20 or
odds ratios near 1.0) to substantial (standardized effect sizes
well in excess of 0.80 or odds ratios of 2.0-3.0 or more). The
variability in prevalence or magnitude of shoulder dysfunction
may be attributed in part to the diversity of outcome measures
and the variety of methods by which even similar outcomes were
assessed and reported in the literature. Levangie and Drouin17
noted that 10 of the 22 reviewed studies used patient self-report
of loss of strength, ROM, or functional ability. Two other studies
used simple observation of impairments such as ROM. In most
of these studies, the data were then dichotomized into present or
absent. Of the studies that measured ROM objectively, 7 reported
actual ranges, while 5 dichotomized their findings based on
losses of as little as 10° of motion.17
Shoulder impairments and functional limitations post-breast
cancer treatment may not only affect function and quality of life,
but may also increase the potential for subsequent pathology.
Two studies using 3-dimensional motion analysis both came to
7

the conclusion that individuals treated for breast cancer were
more likely to have internally rotated scapula.15,21 An increase in
scapular internal rotation may elevate the risk for impingement
problems.22 Yang et al23 found that 7.1% of his breast cancer
cohort had symptoms of rotator cuff disease at 12 months after
surgery. If impairments and limitations that place a person
treated for breast cancer at increased risk for later pathology can
be identified, these impairments can be addressed with interventions targeted at interrupting the causal chain of events. Evidence
does exist that physical therapy treatment can improve shoulder
function in individuals treated for breast cancer.24 We still do not
have the tools, however, to demonstrate our ability to prevent
dysfunction or future pathology through surveillance.
ONCOLOGY SECTION TASK FORCE ON BREAST
CANCER OUTCOMES: CLINICAL MEASURES OF
UPPER EXTREMITY FUNCTION
The evidence to date indicates that individuals treated for
breast cancer may experience upper extremity functional limitations 12 months or more after treatment,17 that long-term shoulder/arm problems in this population are significantly associated
with poor quality of life,18 that shoulder limitations may lead to
pathology over time,23 and that these sequelae might be modified
with physical therapy surveillance and intervention.24 To truly
understand how and when to intervene and what interventions
are effective in preventing or resolving shoulder dysfunction in
the breast cancer population, valid and reliable measures must be
available for the purposes described by Deyo et al.3
The Shoulder Subgroup of the Breast Cancer EDGE Task
Force was charged with reviewing the literature and assessing
clinical measures of the upper extremity. The group divided
relevant outcomes into 3 categories: scapular measures (body
structure and function), shoulder/glenohumeral measures (body
structure and function), and upper extremity function (activity/
participation measures). Three working groups were formed,
each taking one of the 3 categories of clinical measures. After
completing preliminary work, the group determined that a
modification of the StrokEDGE 4-point recommendation scale
was warranted. Many tests and measurements thought to be
potentially appropriate for use in the breast cancer population
were designed for other patient populations. Because there was
concern that tests and measures might behave differently in the
breast cancer population, the recommendation scale was revised
to reflect whether psychometric properties for a measure had
been obtained or used in studies with individuals treated for
breast cancer (Table 2).
At the Combined Sections Meeting in 2012, the Breast
Cancer EDGE Task Force’s subgroup on Clinical Measures of
Upper Extremity Function presented its findings. The presenters
asked Rehabilitation Oncology for the opportunity to also present
their findings to the entire Oncology Section. The goal of publishing these papers is to disseminate the EDGE recommendations
on measures that can or should be used for individuals treated
for breast cancer. Each paper also includes existing measures that
8

Table 2. Breast Cancer EDGE Rating Scale
Highly
Recommend

Highly recommended; the outcome has good
psychometric properties and good clinical utility;
the measure has been used in research on individuals with or post breast cancer.

3

Recommend

Recommended; the outcome measure has good
psychometric properties and good clinical utility;
no published evidence that the measure has been
applied to research on individuals with or post
breast cancer.

2A

Unable to
Recommend at
this time

Unable to recommend at this time; there is insufficient information to support a recommendation
of this outcome measure; the measure has been
used in research on individuals with or post breast
cancer.

2B

Unable to
Recommend at
this time

Unable to recommend at this time; there is insufficient information to support a recommendation
of this outcome measure; no published evidence
that the measure has been applied to research on
individuals with or post breast cancer.

1

Do not
Recommend

4

Poor psychometrics &/or poor clinical utility
(time, equipment, cost, etc.).

require validation or further validation in the breast cancer population, as well as identification of areas where clinically relevant
measures of upper extremity are still quite inadequate. Until
valid, reliable, and clinically useful measures of upper extremity
function are both available and in widespread use in those treated
for breast cancer, we will be challenged in our ability to definitively demonstrate the effects of breast cancer on function and
quality of life, as well as to justify the need for routine surveillance and periodic intervention in this population.
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CANCER EDGE TASK FORCE OUTCOME MEASURE RATING FORM
(Adapted from Neurology Section EDGE form)
Instrument name:
Reviewer:
ICF Domain (check all that apply):
Type of measure:

_____body function/structure

_____ performance-based

_____ activity

_____participation

_____self-report

Languages available:
Population developed in:
Validated populations:
Instrument properties
Reliability (test-retest, intra-rater, inter-rater)
Validity (concurrent, criterion-related, predictive)
Ceiling/ floor effects
Sensitivity to change (responsiveness, MCID, MDC)
Reference Values for Interpretation
Instrument use
Equipment required
Time to complete
How is the instrument scored? (eg, total score, subscales,
etc.)
Level of client participation required (proxy participation?)
Effect of Training (if applicable)
Is this tool appropriate for individual patient decision-making? Yes _____
(available MDC, MCID, Likelihood ratios?)
Comments:

No _____

Availability:
Score Sheets: _____ Public Domain

_____Available but copyrighted

_____Unavailable

Instructions:

_____Available but copyrighted

_____Unavailable

_____ Public Domain

Computer-based or Web-based scoring available: ____ yes

_____ no

Purchase price:
Purchase Contact Info:
Assessment of Overall Usefulness (Primary Reviewer):

Secondary Reviewer Comments:

Overall Task Force Agreement with Recommendations:
Reference List:
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